These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17063499)

  • 1. The role of FDG-PET/CT in suspected recurrence of breast cancer.
    Radan L; Ben-Haim S; Bar-Shalom R; Guralnik L; Israel O
    Cancer; 2006 Dec; 107(11):2545-51. PubMed ID: 17063499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
    Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.
    Champion L; Brain E; Giraudet AL; Le Stanc E; Wartski M; Edeline V; Madar O; Bellet D; Pecking A; Alberini JL
    Cancer; 2011 Apr; 117(8):1621-9. PubMed ID: 21472709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
    Israel O; Mor M; Guralnik L; Hermoni N; Gaitini D; Bar-Shalom R; Keidar Z; Epelbaum R
    J Nucl Med; 2004 Dec; 45(12):2045-51. PubMed ID: 15585480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence].
    Palomar Muñoz A; García Vicente AM; Talavera Rubio MP; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; León Martín A; Cordero García JM; Soriano Castrejón A
    Rev Esp Med Nucl; 2010; 29(3):100-8. PubMed ID: 20392542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.
    Eubank WB; Mankoff D; Bhattacharya M; Gralow J; Linden H; Ellis G; Lindsley S; Austin-Seymour M; Livingston R
    AJR Am J Roentgenol; 2004 Aug; 183(2):479-86. PubMed ID: 15269044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities.
    Filippi V; Malamitsi J; Vlachou F; Laspas F; Georgiou E; Prassopoulos V; Andreou J
    Nucl Med Commun; 2011 Feb; 32(2):85-90. PubMed ID: 21127445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
    Siggelkow W; Rath W; Buell U; Zimny M
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.